Oppenheimer & Co. Inc. Buys 8,271 Shares of Eli Lilly and Company $LLY

Oppenheimer & Co. Inc. boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 10.5% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 86,953 shares of the company’s stock after purchasing an additional 8,271 shares during the quarter. Eli Lilly and Company comprises 1.1% of Oppenheimer & Co. Inc.’s portfolio, making the stock its 12th largest holding. Oppenheimer & Co. Inc.’s holdings in Eli Lilly and Company were worth $100,612,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Park Avenue Securities LLC lifted its position in shares of Eli Lilly and Company by 4.7% during the 3rd quarter. Park Avenue Securities LLC now owns 37,258 shares of the company’s stock worth $43,110,000 after purchasing an additional 1,656 shares during the last quarter. Segment Wealth Management LLC grew its holdings in Eli Lilly and Company by 0.6% in the 3rd quarter. Segment Wealth Management LLC now owns 15,657 shares of the company’s stock valued at $18,116,000 after buying an additional 93 shares during the last quarter. Rainey & Randall Wealth Advisors Inc. grew its holdings in Eli Lilly and Company by 4.9% in the 3rd quarter. Rainey & Randall Wealth Advisors Inc. now owns 427 shares of the company’s stock valued at $494,000 after buying an additional 20 shares during the last quarter. Verdence Capital Advisors LLC grew its holdings in Eli Lilly and Company by 10.5% in the 3rd quarter. Verdence Capital Advisors LLC now owns 7,979 shares of the company’s stock valued at $9,233,000 after buying an additional 756 shares during the last quarter. Finally, Mill Capital Management LLC increased its position in Eli Lilly and Company by 0.3% in the 3rd quarter. Mill Capital Management LLC now owns 25,509 shares of the company’s stock worth $29,516,000 after buying an additional 87 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Retatrutide produced a major clinical win over Ozempic. In a Phase 3 head-to-head trial, the investigational drug delivered average weight loss of approximately 44–47 pounds, or 20%–21%, after 80 weeks, compared with about 21 pounds for Ozempic. Retatrutide also reduced A1C by 2.2% versus 1.8% for Ozempic 2 mg. The results strengthen Lilly’s long-term position in the highly competitive obesity-drug market, although retatrutide is not yet approved. Lilly retatrutide trial results
• Positive Sentiment: A federal judge rejected Novo Nordisk’s effort to block Lilly’s weight-loss drug advertising, finding insufficient evidence of meaningful sales harm. The ruling preserves Lilly’s ability to market Zepbound and its obesity portfolio using the challenged campaign. Court rejects Novo advertising challenge
• Positive Sentiment: Lilly is broadening its pipeline beyond GLP-1 medicines, with Kisunla in neuroscience and Taltz and newer therapies in immunology expected to support growth. The company also licensed the SpeechDx Alzheimer’s dataset to advance speech-based disease markers. Lilly neuroscience and immunology outlook
• Positive Sentiment: Bernstein raised its Lilly price target to $1,450 from $1,385, reflecting continued confidence in the company’s growth outlook. Lilly also declared a quarterly dividend of $1.73 per share.
• Neutral Sentiment: Patrik Jonsson will retire as head of Lilly International at year-end 2026, with Ilya Yuffa taking over the expanded Lilly Global Markets role on January 1, 2027. The transition is planned, but investors may monitor execution as the company consolidates its global commercial structure. Lilly leadership transition
• Negative Sentiment: Investors face substantial earnings-event risk ahead of Thursday’s report. Analysts expect roughly $6.67 in earnings per share and $22.62 billion in revenue, while options markets imply a potentially large post-earnings move. Reports that recent EPS estimates have fallen sharply add to caution.
• Negative Sentiment: About 16% of employers are reportedly considering reducing coverage for weight-loss medicines. Any broader reimbursement pullback could pressure demand for Zepbound and limit the market’s near-term growth assumptions. Employer weight-loss drug coverage concerns
• Negative Sentiment: Two Massachusetts hospitals joined a lawsuit alleging Lilly’s digital tools may put patient privacy at risk. The claims remain unresolved, but adverse findings could create legal, regulatory, and reputational costs. Patient privacy lawsuit

Eli Lilly and Company Stock Up 0.6%

Shares of LLY opened at $1,289.36 on Thursday. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The company has a 50-day moving average price of $1,192.52 and a two-hundred day moving average price of $1,089.35. The stock has a market cap of $1.21 trillion, a price-to-earnings ratio of 43.27, a P/E/G ratio of 1.71 and a beta of 0.46. Eli Lilly and Company has a 12 month low of $809.63 and a 12 month high of $1,321.21.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The company had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. During the same period in the prior year, the company posted $6.31 EPS. The company’s revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities analysts predict that Eli Lilly and Company will post 33.22 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 annualized dividend and a yield of 0.5%. Eli Lilly and Company’s payout ratio is currently 23.22%.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 2,000 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president directly owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $15,958,170 in the last 90 days. 0.14% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

LLY has been the subject of a number of research analyst reports. UBS Group set a $1,376.00 price target on Eli Lilly and Company in a report on Friday, August 7th. Wells Fargo & Company raised their price objective on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the stock an “overweight” rating in a research note on Monday, September 28th. Berenberg Bank set a $1,400.00 target price on shares of Eli Lilly and Company and gave the stock a “buy” rating in a research report on Tuesday, September 15th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $1,500.00 target price on shares of Eli Lilly and Company in a research note on Monday, October 12th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $1,320.25.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.